Advertisement
Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA
(RTTNews) - Takeda Canada Inc., the Canadian arm of Japan's Takeda Pharmaceutical Co. Ltd. (TAK) on Wednesday entered into a contract with Canadian Blood Services (CBS) for GLASSIA (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1).
Glassia has been approved to be listed on the CBS Plasma Protein and Related Products (PPRP) formulary with specific criteria for reimbursement. This marks Takeda's entry into the Alpha-1 community in Canada, building on the company's commitment to developing innovative treatments for rare diseases.
Glassia is a liquid medicine for infusion containing human Alpha 1-Proteinase Inhibitor (A1-PI) also known as alpha-1 antitrypsin (A1AT), which is purified from human blood.
read more
Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis
Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
RTTNews
|
hace 547
Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia
Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia disorders.
RTTNews
|
hace 687
Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease
Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with ENTYVIO intravenous (IV).
RTTNews
|
hace 699
Takeda Reports Positive Topline Results Of Phase 2b Study Of TAK-279 For Active Psoriatic Arthritis
Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) announced Monday positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis.
RTTNews
|
hace 701
UK Labor Market Cools In Q2
The U.K. labor market softened in the second quarter as wage growth eased, the unemployment rate held steady at a four-year high and job vacancies continued to decline sharply, official data revealed on Tuesday. The ILO jobless rate held steady at 4.7 percent in the second quarter, figures from the Office for National Statistics revealed and was in line with expectations.
RTTNews
|
hace 2h 27min
U.S. Consumer Prices Increase 0.2% In July, In Line With Estimates
Consumer prices in the U.S. increased in line with economist estimates in the month of July, according to a report released by the Labor Department on Tuesday. The Labor Department said its consumer price index rose by 0.2 percent in July after climbing by 0.3 percent in June. The modest increase matched expectations.
RTTNews
|
hace 2h 39min
Cardinal Health Lifts FY26 Outlook, But Stock Down As Q4 Revenues Miss Street; To Buy Solaris Health
Shares of Cardinal Health, Inc. were losing around 6% in the pre-market activity after the company's fourth-quarter top line missed the market view, even as profit beat the Street. In addition, the health care service provider raised its fiscal 2026 outlook, also above market estimates. Separately, Cardinal Health announced that its multi-specialty management services organization or MSO platform
RTTNews
|
hace 3h 3min
U.S. Consumer Prices Increase In Line With Estimates In July
Consumer prices in the U.S. increased in line with economist estimates in the month of July, according to a report released by the Labor Department on Tuesday.
RTTNews
|
hace 3h 23min
